Therefore, molecular therapies directed at nucleic acid structures formed in the C9-NRE mutation DNA region are a promising therapeutic target for mitigating pathological hallmarks of C9-NRE-linked ALS/FTD disease in vitro and in vivo. The gene discussed is C9; the disease is frontotemporal dementia.